The present disclosure relates to 1,2-dihydro-2-oxoquinoline compounds of the formula (I), and compositions containing them. There is also disclosed a process for the preparation of above said novel compounds, and compositions containing them. The compounds of the present invention are useful in the treatment/prevention of various disorders that are mediated by 5-HT4 receptor activity. Some examples of the disclosed compounds are: N-[(5-Phenyl-2-azatricyclo[3.3 ,1,13,7]dec-2-yl) propyl]-4-hydroxy-1-isopropyl-2-oxo-1 ,2-dihydroquinoline-3-carboxamide hydrochloride N-(1-Butyl piperidin-4-yl)-4-hydroxy-1-isopropyl-2-oxo-1,2-dihydroquinoline-3 carboxamide hydrochloride and N-(4-(Pyrrolidin-1-yl) cyclohexyl)-4-hydroxy-1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxamide hydrochloride.
